Advertisement
Canada markets closed
  • S&P/TSX

    24,072.51
    -30.20 (-0.13%)
     
  • S&P 500

    5,751.13
    +55.19 (+0.97%)
     
  • DOW

    42,080.37
    +126.13 (+0.30%)
     
  • CAD/USD

    0.7321
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    73.82
    +0.25 (+0.34%)
     
  • Bitcoin CAD

    85,127.38
    -485.44 (-0.57%)
     
  • XRP CAD

    0.73
    +0.00 (+0.16%)
     
  • GOLD FUTURES

    2,640.30
    +4.90 (+0.19%)
     
  • RUSSELL 2000

    2,194.98
    +1.89 (+0.09%)
     
  • 10-Yr Bond

    4.0330
    +0.0070 (+0.17%)
     
  • NASDAQ futures

    20,276.00
    -22.50 (-0.11%)
     
  • VOLATILITY

    21.42
    -1.22 (-5.39%)
     
  • FTSE

    8,190.61
    -113.01 (-1.36%)
     
  • NIKKEI 225

    39,261.74
    +324.20 (+0.83%)
     
  • CAD/EUR

    0.6670
    -0.0002 (-0.03%)
     

With 75% institutional ownership, Creo Medical Group PLC (LON:CREO) is a favorite amongst the big guns

Key Insights

  • Institutions' substantial holdings in Creo Medical Group implies that they have significant influence over the company's share price

  • The top 10 shareholders own 51% of the company

  • Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company

Every investor in Creo Medical Group PLC (LON:CREO) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 75% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.

In the chart below, we zoom in on the different ownership groups of Creo Medical Group.

Check out our latest analysis for Creo Medical Group

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Creo Medical Group?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Creo Medical Group does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Creo Medical Group, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. We note that hedge funds don't have a meaningful investment in Creo Medical Group. Canaccord Genuity Asset Management Limited is currently the largest shareholder, with 12% of shares outstanding. For context, the second largest shareholder holds about 9.6% of the shares outstanding, followed by an ownership of 5.0% by the third-largest shareholder.

On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Creo Medical Group

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Creo Medical Group PLC. It has a market capitalization of just UK£115m, and insiders have UK£5.2m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, who are usually individual investors, hold a 17% stake in Creo Medical Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Creo Medical Group is showing 1 warning sign in our investment analysis , you should know about...

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com